Evaluation of probiotic susceptibility of virulent Aeromonas sp. by a study on gut histology of Cyprinus carpio

Thành, Nguyễn Chí; Rajeswari, V. Devi; Narayanan, Mathiyazhagan; Kandasamy, Sabariswaran; Chinnathambi, Arunachalam; Alharbi, Sulaiman Ali; Le, Quyet Van; Brindhadevi, Kathirvel

doi:10.1016/j.procbio.2021.10.023

Cited by 11 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In children, MBDs can cause sequential developmental abnormalities, skeletal abnormalities, non-traumatic fractures, and functional limitations of motor growth and function ( Skowrońska-Jóźwiak and Lorenc, 2006 ; Cavalier et al , 2016 ). The underlying reason for MBDs determines a remedy; early diagnosis and treatment of lifestyle factors are critical for an individual’s bone health ( Thanh et al , 2021 ). Bone mineral metabolism necessarily requires a well-balanced, rich diet, with vitamin D and calcium, as well as moderate exercise ( Chinoy et al , 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Metabolic Bone Diseases and New Drug Developments

Vijayakumar

Kim

2022

Biomol Ther (Seoul)

View full text Add to dashboard Cite

Metabolic bone diseases are serious health issues worldwide, since several million individuals over the age of 50 are at risk of bone damage and should be worried about their bone health. One in every two women and one in every four men will break a bone during their lifetime due to a metabolic bone disease. Early detection, raising bone health awareness, and maintaining a balanced healthy diet may reduce the risk of skeletal fractures caused by metabolic bone diseases. This review compiles information on the most common metabolic bone diseases (osteoporosis, primary hyperparathyroidism, osteomalacia, and fluorosis disease) seen in the global population, including their symptoms, mechanisms, and causes, as well as discussing their prevention and the development of new drugs for treatment. A large amount of research literature suggests that balanced nutrition and balanced periodic supplementation of calcium, phosphate, and vitamin D can improve re-absorption and the regrowth of bones, and inhibit the formation of skeletal fractures, except in the case of hereditary bone diseases. Meanwhile, new and improved drug formulations, such as raloxifene, teriparatide, sclerostin, denosumab, and abaloparatide, have been successfully developed and administered as treatments for metabolic bone diseases, while others (romososumab and odanacatib) are in various stages of clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolic Bone Diseases and New Drug Developments

Vijayakumar

Kim

2022

Biomol Ther (Seoul)

View full text Add to dashboard Cite

show abstract

“…Although medicinal plant extracts possess excellent potential for treating bacterial infections caused by drugs resistant pathogens. It is interesting to know that >5% of the world's plant species have indeed been studied as potential medicines thus far, with the remaining 95% still yet to be studied [8][9][10]. Interestingly, the phytochemicals from the plant extract also have the potential to synthesize the nanoparticles with pharmaceutically valuable, therapeutics [3,11].…”

Section: Introductionmentioning

confidence: 99%

Green Synthesis of Chitosan Nanoparticles Using of Martynia annua L. Ethanol Leaf Extract and Their Antibacterial Activity

et al. 2022

View full text Add to dashboard Cite

The herbal-based drug isolation-related research has increased recently around the globe. Accordingly, the current study was designed to evaluate the phytochemical content of ethanol extract of Martynia annua and its chitosan nanoparticles (MA-CNPs) antibacterial activity against bacterial pathogens such as Bacteroides fragilis, Streptococcus oralis MTCC 2696, Propionibacterium acnes MTCC 1951, Pseudomonas aeruginosa MTCC 424, Staphylococcus aureus MTCC 2940, E. coli MTCC 443, Bacillus cereus MTCC 441, Streptococcus mutans MTCC 890, Aeromonas hydrophila MTCC 12301, and Streptococcus faecalis by agar well diffusion methods. The obtained results showed that the ethanol extract of M. annua contains more pharmaceutically valuable phytochemicals than other solvent extracts and its mediated chitosan nanoparticles showed effective antibacterial activities. The ethanol extract also effectively reduced, capped, and stabilized the chitosan into MA-CNPs. The green synthesized MA-CNPs were characterized and confirmed through UV-visible spectrophotometer, FT-IR, SEM, and DLS analyses. The MA-CNPs exhibited considerable antibacterial activity in the order of Bacteroides fragilis > Streptococcus oralis > Propionibacterium acnes > Pseudomonas aeruginosa > Staphylococcus aureus > E. coli > Bacillus cereus > Streptococcus mutans > Aeromonas hydrophila> Streptococcus faecalis. Finally, the results strongly recommended that the ethanol extract of M. annua-mediated chitosan nanoparticles could be considered an effective nanomaterial to control microbial pathogens. Further, therapeutical uses of MA-CNPs need in vitro and in vivo investigation.

show abstract